Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

NCT03007030 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

55

Enrollment

OTHER

Sponsor class

Conditions

CD30-Positive Neoplastic Cells Present
Malignant Mesothelioma

Interventions

DRUG: Brentuximab Vedotin
OTHER: Laboratory Biomarker Analysis

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]